456 related articles for article (PubMed ID: 15328081)
1. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081
[TBL] [Abstract][Full Text] [Related]
2. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
[TBL] [Abstract][Full Text] [Related]
3. Virological fitness of HIV in patients with resistance to enfuvirtide.
Chibo D; Roth N; Roulet V; Skrabal K; Gooey M; Carolan L; Nicholls J; Papadakis A; Birch C
AIDS; 2007 Sep; 21(14):1974-7. PubMed ID: 17721108
[TBL] [Abstract][Full Text] [Related]
4. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
[TBL] [Abstract][Full Text] [Related]
5. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
[TBL] [Abstract][Full Text] [Related]
6. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
[TBL] [Abstract][Full Text] [Related]
7. Resistance to enfuvirtide, the first HIV fusion inhibitor.
Greenberg ML; Cammack N
J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.
Charpentier C; Jenabian MA; Piketty C; Karmochkine M; Tisserand P; Laureillard D; Bélec L; Si-Mohamed A; Weiss L
Scand J Infect Dis; 2011 May; 43(5):373-9. PubMed ID: 21341978
[TBL] [Abstract][Full Text] [Related]
9. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen.
Cabrera C; Marfil S; García E; Martinez-Picado J; Bonjoch A; Bofill M; Moreno S; Ribera E; Domingo P; Clotet B; Ruiz L
AIDS; 2006 Oct; 20(16):2075-80. PubMed ID: 17053353
[TBL] [Abstract][Full Text] [Related]
10. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
Su C; Melby T; DeMasi R; Ravindran P; Heilek-Snyder G
J Clin Virol; 2006 Aug; 36(4):249-57. PubMed ID: 16765082
[TBL] [Abstract][Full Text] [Related]
11. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy.
Poveda E; Rodés B; Lebel-Binay S; Faudon JL; Jimenez V; Soriano V
J Clin Virol; 2005 Dec; 34(4):295-301. PubMed ID: 16286053
[TBL] [Abstract][Full Text] [Related]
13. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
Lalezari JP; Bellos NC; Sathasivam K; Richmond GJ; Cohen CJ; Myers RA; Henry DH; Raskino C; Melby T; Murchison H; Zhang Y; Spence R; Greenberg ML; Demasi RA; Miralles GD;
J Infect Dis; 2005 Apr; 191(7):1155-63. PubMed ID: 15747252
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy.
Poveda E; Briz V; Paraskevis D; Barreiro P; Hatzakis A; Soriano V
AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1078-82. PubMed ID: 17919101
[TBL] [Abstract][Full Text] [Related]
15. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.
Marcial M; Lu J; Deeks SG; Ziermann R; Kuritzkes DR
J Clin Microbiol; 2006 Sep; 44(9):3384-7. PubMed ID: 16954280
[TBL] [Abstract][Full Text] [Related]
16. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.
Xu L; Pozniak A; Wildfire A; Stanfield-Oakley SA; Mosier SM; Ratcliffe D; Workman J; Joall A; Myers R; Smit E; Cane PA; Greenberg ML; Pillay D
Antimicrob Agents Chemother; 2005 Mar; 49(3):1113-9. PubMed ID: 15728911
[TBL] [Abstract][Full Text] [Related]
17. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
[TBL] [Abstract][Full Text] [Related]
18. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
[TBL] [Abstract][Full Text] [Related]
20. Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K).
Tolstrup M; Selzer-Plön J; Laursen AL; Bertelsen L; Gerstoft J; Duch M; Pedersen FS; Ostergaard L
AIDS; 2007 Feb; 21(4):519-21. PubMed ID: 17301572
[No Abstract] [Full Text] [Related]
[Next] [New Search]